Zosano Pharma Appoints New CMO, Fills Two New Operations Management Positions to Bolster Leadership Team
01 5월 2015 - 5:05AM
Zosano Pharma Corporation (Nasdaq:ZSAN) announced today important
leadership additions and changes with Thorsten von Stein, M.D.,
Ph.D. returning to the company as Chief Medical Officer, Laxmi Peri
joining as Sr. Vice President, Operations, and Eric Scharin joining
as Vice President, Technical Operations. Mr. Peri will be heading
the Operations group including manufacturing and engineering, while
Nandan Oza has resigned as Chief Operations Officer and will move
to a consulting role with the company.
"Thorsten, Laxmi and Eric are welcome additions to Zosano's
leadership team at an important phase in our company's growth. We
are gearing up to further advance our portfolio of proprietary and
partnered development programs with multiple clinical trials and
are expanding our manufacturing activities in the coming months,"
said Zosano's Chief Executive Officer Vikram Lamba.
Dr. von Stein resumes his former role at Zosano as Chief Medical
Officer having previously served in that position from 2009 to
2014. Before joining Zosano, Dr. von Stein served at Tercica as
Senior Vice President and Chief Medical Officer from 2005 to 2009.
From 2001 to 2005, he served as Chief Medical Officer and
previously Vice President of Clinical Development at NeurogesX. Dr.
von Stein held positions of increasing responsibility in clinical
development and project management from 1994 to 2001 at Roche Palo
Alto and F. Hoffmann-La Roche AG in Basel, Switzerland. Dr. von
Stein received his medical degree from Munich University, Germany,
and his Ph.D. in Computer Science from the University of Hamburg,
Germany.
Laxmi Peri joins Zosano after 11 years as Vice President,
R&D at Thoratec Corporation, a world leader in research,
development and manufacturing of medical devices for circulatory
support. At Thoratec, Mr. Peri was a part of the executive team
that grew the business from revenues of $100 million to more than
$500 million in a span of ten years. Prior to joining Thoratec, Mr.
Peri was with St. Jude Medical for ten years in a variety of
leadership positions in operations management and R&D. He has
extensive experience in process development, product development
and manufacturing management. Mr. Peri holds an M.B.A. from the
University of Minnesota, and a B.S. and an M.S. in Mechanical
Engineering.
Eric Scharin most recently served at Zogenix as Senior Director
of Engineering and Product Industrialization. He directed all
technical programs associated with design engineering, process
engineering, facility/project engineering, and validation for
Zogenix devices and pharmaceuticals throughout the product
lifecycle. Prior to joining Zogenix, Mr. Scharin served at Tercica
as Director of Manufacturing, where he successfully completed the
technology transfer of rhIGF-1, and served in various roles within
the manufacturing function. Prior to Tercica, Mr. Scharin worked
for Covance Biotechnology and Biogen. He completed a B.S. in
Chemical Engineering at Caltech, and an M.S.C.E.P in Chemical
Engineering at MIT.
About Zosano Pharma
Zosano Pharma Corporation is a clinical-stage specialty
pharmaceutical company that has developed a proprietary transdermal
microneedle patch system to deliver its formulations of existing
drugs through the skin for the treatment of a variety of
indications. Zosano's microneedle patch system offers rapid onset,
consistent drug delivery, improved ease of use and room-temperature
stability, benefits that the company believes often are unavailable
using oral formulations or injections. Zosano's microneedle patch
system has the potential to deliver numerous medications for a wide
variety of indications in commercially attractive markets. It has
been tested in more than 400 patients with over 30,000 patches
successfully applied to humans in Phase 1 and Phase 2 clinical
studies. Learn more at www.zosanopharma.com.
Forward-Looking Statements
This press release contains forward-looking statements regarding
the timing of expected clinical trials and manufacturing activities
and other future events and expectations. Readers are urged to
consider statements that include the words "may," "will," "would,"
"could," "should," "might," "believes," "estimates," "projects,"
"potential," "expects," "plans," "anticipates," "intends,"
"continues," "forecast," "designed," "goal," "unaudited,"
"approximately" or the negative of those words or other comparable
words to be uncertain and forward-looking. These statements are
subject to risks and uncertainties that are difficult to predict
and actual outcomes may differ materially. These include risks and
uncertainties, without limitation, associated with the process of
discovering, developing and commercializing products that are safe
and effective for use as human therapeutics, risks inherent in the
effort to build a business around such products and other risks and
uncertainties described under the heading "Risk Factors" in our
Annual Report on Form 10-K for the year ended December 31, 2014
filed with Securities and Exchange Commission on March 26, 2015.
Although we believe that the expectations reflected in these
forward-looking statements are reasonable, we cannot in any way
guarantee that the future results, level of activity, performance
or events and circumstances reflected in forward-looking statements
will be achieved or occur. All forward-looking statements are based
on information currently available to Zosano and Zosano assumes no
obligation to update any such forward-looking statements.
CONTACT: Zosano Contact:
Vikram Lamba
Chief Executive Officer
510-745-1200
Investor Contact:
Paul Chun
Westwicke Partners
858-356-5931
paul.chun@westwicke.com
Media Contact:
Jamie Lacey-Moreira
PressComm PR, LLC
410-299-3310
jamielacey@presscommpr.com
Zosano Pharma (NASDAQ:ZSAN)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Zosano Pharma (NASDAQ:ZSAN)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024